Advertisement
We are pleased to announce the appointment of Ms. Patricia Faci Villalobosas the new Vice President of Operations of Genomma Lab Internacional S.A.B deC.V., reporting to our Chief Executive Officer, Rodrigo Herrera. As VicePresident of Operations, Ms. Faci will lead the Sales, Supply Chain, IT,Finance and Administration, R&D and International areas while our CEO willcontinue to oversee Marketing, Commercial Strategy, and Corporate Relationsdirectly.
Advertisement
Ms. Faci was Chief Executive Officer of Grupo Quan for more than 4 years.Previously with the same group she acted as Chief Executive Officer ofLaboratorios Kener and as Chief Financial Officer for "Helados Holanda."Before Grupo Quan, Ms. Faci held various administrative and operativepositions at DESC: GIRSA (Grupo Industrial Resistol). Ms. Faci was Presidentof CANIFARMA (Camara Nacional de la Industria Farmaceutica) (2005-2007); BoardMember of CANIFARMA in 2004; Vice President of CANIFARMA in 2003 and hasparticipated in many industry-related chambers as well as associations. Ms.Faci earned a graduate degree in Chemical Engineering from the Universidad LaSalle and participated in Top Management courses at the Instituto Panamericanode Alta Direccion de Empresas.
We believe that with Ms. Faci's management expertise and leadership,Genomma Lab will be in a better position to capitalize the existingopportunities in the market.
Additionally, we are also pleased to announce the incorporation of Mr.Oscar Villalobos-Torres as the Company's new Chief Financial Officer,substituting Ms. Kristi King Etchberger.
Mr. Villalobos has worked in the past 10 years principally in Grupo IMSAwhere he worked in various finance and administrative positions. He alsomanaged diverse M&A transactions and was involved in financial and strategicplanning activities. Before, Mr. Villalobos lead the treasury and planningareas in Internacional de Ceramica from 1993 to 1998. Mr. Villalobos obtainedan MBA from the Universidad de Chihuahua; obtained a graduate degree inAdministration and Finance from University of Texas; has performed managerialcourses in the Instituto Panamericano de Alta Direccion de Empresa; hasstudied International Business and Economic Law at George WashingtonUniversity; and has a graduate degree in Finance from Instituto Tecnologico yde Estudios Superiores de Monterrey.
Company Description
Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growingover-the-counter pharmaceutical and personal care products companies inMexico. Genomma develops, sells and markets a broad range of premium brandedproducts, many of which are leaders in the categories in which they compete interms of sales and market share. Through a combination of a successful newproducts development process, consumer-oriented marketing, a broad retaildistribution network and a low-cost, highly flexible operating model, theCompany has grown its revenue at a compounded annual growth rate of 64.4% from2005 to 2007.
The Company had net sales of Ps. 1,872.9 million and EBITDA of Ps. 460.5million in 2007. Genomma's shares are listed on the Mexican Stock Exchangeunder the ticker symbol "LAB.B" (Bloomberg: labb.mx).
Web Site: www.genommalab.com
SOURCE Genomma Lab Internacional
